Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study.
Sabine KayserRamy RahméDavid Martínez-CuadrónGabriel GhiaurXavier ThomasMarta SobasAgnes Guerci-BreslerAna GarridoArnaud PigneuxCristina GilEmmanuel RaffouxMar TormoNorbert VeyJavier de la SernaOlga SalameroEva LengfelderMark J LevisPierre FenauxMiguel A SanzUwe PlatzbeckerRichard F SchlenkLionel AdèsPau MontesinosPublished in: Leukemia (2020)
Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73.4 years) treated either with ATO+ all-trans retinoic acid (ATO/ATRA; n = 26), CTX/ATRA + ATO during consolidation (CTX/ATRA/ATO; n = 148), or with CTX/ATRA (n = 259). Median follow-up for overall survival (OS) was 4.8 years. Complete remissions (CR) were achieved in 92% with ATO/ATRA and 82% with CTX/ATRA; induction death rates were 8% and 18%, respectively. For analysis of postremission outcomes we combined the ATO/ATRA and CTX/ATRA/ATO groups (ATO/ATRA ± CTX). Cumulative incidence of relapse (CIR) was significantly lower after ATO/ATRA ± CTX compared with CTX/ATRA (P < 0.001). The same held true when restricting the analysis according to the treatment period after the year 2000. OS of patients in CR1 was not different between ATO/ATRA ± CTX compared with CTX/ATRA (P = 0.20). High (>10 × 109/l) white blood cell (WBC) counts at diagnosis were associated with higher CIR (P < 0.001) compared with lower WBC in the CTX/ATRA group, but not in the ATO/ATRA ± CTX group (P = 0.48). ATO, when added to ATRA or CTX/ATRA is feasible and effective in elderly patients for remission induction and consolidation, particularly in patients with high WBC at diagnosis.
Keyphrases
- klebsiella pneumoniae
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- stem cells
- multidrug resistant
- escherichia coli
- prognostic factors
- physical activity
- squamous cell carcinoma
- radiation therapy
- acute myeloid leukemia
- risk factors
- mesenchymal stem cells
- heavy metals
- single cell
- systemic lupus erythematosus
- locally advanced